Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Other Accumulated Expenses data on record, last reported at $308000.0 in Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 30.16% to $308000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $308000.0, a 30.16% decrease, with the full-year FY2025 number at $258000.0, down 44.28% from a year prior.
  • Other Accumulated Expenses reached $308000.0 in Q1 2026 per FULC's latest filing, up from $258000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for FULC hit a ceiling of $463000.0 in Q4 2024 and a floor of $9000.0 in Q1 2023.
  • A 5-year average of $231117.6 and a median of $258000.0 in 2025 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 93.28% in 2023, then surged 4177.78% in 2024.
  • Tracing FULC's Other Accumulated Expenses over 5 years: stood at $105000.0 in 2022, then surged by 277.14% to $396000.0 in 2023, then grew by 16.92% to $463000.0 in 2024, then tumbled by 44.28% to $258000.0 in 2025, then grew by 19.38% to $308000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for FULC at $308000.0 in Q1 2026, $258000.0 in Q4 2025, and $236000.0 in Q3 2025.